Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer (mCRC) program continues to show our lead candidate onvansertib demonstrates an objective...

Related Keywords

Giessen ,Hessen ,Germany ,Berlin ,Acta Oncologica ,Bolus Fluorouracil ,James Levine ,Randolph Hecht ,Kiki Patel ,Williamf Novotny ,Fairoozf Kabbinavar ,Van Cutsem ,Brent Perrou ,Richa Kumari ,Tod Smeal ,Charles Monahan ,Michael Mccleod ,Fairooz Kabbinavar ,Joseph Schulz ,Johnt Hamm ,Mark Erlander ,Betty Nelson ,Taral Patel ,Exchange Commission ,Cardiff Oncology Inc ,Taft Communications ,Gilmartin Group ,Beretta ,Nasdaq ,Dana Farber Cancer Institute Phase ,Cardiff Oncology ,Dana Farber Cancer Institute ,Bevacizumab Plus Irinotecan ,Metastatic Colorectal Cancer ,New England Journal ,Robert Mass ,First Line Metastatic Colorectal Cancer ,Randomized Phase ,Clinical Oncology ,Lancet Oncol ,Correspondence Lancet Oncol ,Med Oncol ,Private Securities Litigation Reform Act ,Oncology Contact ,Nc ,